Intravenous immunoglobulins contain naturally occurring antibodies that mimic antineutrophil cytoplasmic antibodies and activate neutrophils in a TNFα-dependent and Fc-receptor-independent way

Blood

Volumn 109, Issue 10, 2007, Pages 4376-4382

  Jarius, Sven ^a,b   Eichhorn, Peter ^a   Albert, Michael H ^c   Wagenpfeil, Stefan ^d   Wick, Manfred ^a   Belohradsky, Bernd H ^c   Hohlfeld, Reinhard ^a,b   Jenne, Dieter E ^b   Voltz, Raymond ^a,b,e  

^a UNIVERSITY OF MUNICH   (Germany)

^b MAX PLANCK INSTITUTE OF NEUROBIOLOGY   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN 7S; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; NEUTROPHIL CYTOPLASMIC ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VENIMMUN N;

ARTICLE; GRANULOCYTE; IN VIVO STUDY; NEUTROPHIL; PRIORITY JOURNAL;

EID: 34248186586     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-12-019604     Document Type: Article

References (61)

1. Voltz R, Hohlfeld R. The use of intravenous immunoglobulins in the treatment of neuromuscular disorders. Curr Opin Neurol. 1996;9:360-366.
2. Dalakas MC. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve. 1999;22:1479-1497.
3. Hahn AF. Intravenous immunoglobulin treatment in peripheral nerve disorders: indications, mechanisms of action and side-effects. Curr Opin Neurol. 2000;13:575-582.
4. Wiles CM, Brown P, Chapel H, et al. Intravenous immunoglobulin in neurological disease: a specialist review. J Neurol Neurosurg Psychiatry. 2002;72:440-448.
5. Ropper AH. Current treatments for CIDP. Neurology. 2003;60(Suppl 3):S16-S22.
6. Brannagan TH. Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immunemediated neuropathies. Neurology. 2002;59(Suppl 6):S33-S40.
7. Hughes RA, Raphael JC, Swan AV, Doorn PA. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev. 2004;CD002063.
8. Jolles S, Sewell WA, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol. 2005;142:1-11.
9. Brannagan TH, Nagle KJ, Lange DJ, Rowland LP. Complications of intravenous immune globulin treatment in neurologic disease. Neurology. 1996;47:674-677.
10. Stangel M, Hartung HP, Marx P, Gold R. Side effects of high-dose intravenous immunoglobulins. Clin Neuropharmacol. 1997;20:385-393.
11. Sherer Y, Levy Y, Langevitz P, Rauova L, Fabrizzi F, Shoenfeld Y. Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases. Pharmacology. 2001;62:133-137.
12. Stangel M, Kiefer R, Pette M, Smolka MN, Marx P, Gold R. Side effects of intravenous immunoglobulins in neurological autoimmune disorder: a prospective study. J Neurol. 2003;250:818-821.
13. Bagdasarian A, Tonetta S, Harel W, Mamidi R, Uemura Y. IVIg adverse reactions: potential role of cytokines and vasoactive substances. Vox Sang. 1998;74:74-82.
14. Lemm G. Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy. Neurology. 2002;59(Suppl 6):S28-S32.
15. Gomperts ED, Darr F. Rapid infusion of intravenous immunoglobulin in patients with neuromuscular diseases. Neurology. 2002;58:1444.
16. Voltz R, v Rosen F, Yousry, T, Beck J, Hohlfeld R. Reversible encephalopathy with cerebral vasospasm in a Guillain-Barré syndrome patient treated with intravenous immunoglobulin. Neurology. 1996;46:250-251.
17. Harkness K, Howell SJ, Davies-Jones GA. Encephalopathy associated with intravenous immunoglobulin treatment for Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 1996;60:586.
18. Mathy I, Gille M, Van Raemdonck F, Delbecq J, Depre A. Neurological complications of intravenous immunoglobulin (IVIg) therapy: an illustrative case of acute encephalopathy following IVIg therapy and a review of the literature. Acta Neurol Belg. 1998;98:347-351.
19. Sztajzel R, Le Floch-Rohr J, Eggimann P. High-dose intravenous immunoglobulin treatment and cerebral vasospasm: a possible mechanism of ischemic encephalopathy? Eur Neurol. 1999;41:153-158.
20. Silbert PL, Knezevic WV, Bridge DT. Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis. Neurology. 1992;42:257-258.
21. Steg RE, Lefkowitz DM. Cerebral infarction following intravenous immunoglobulin therapy for myasthenia gravis. Neurology. 1994; 44:1180-1181.
22. Turner B, Wills AJ. Cerebral infarction complicating intravenous immunoglobulin therapy in a patient with Miller Fisher syndrome. J Neurol Neurosurg Psychiatry. 2000;68:790-791.
23. Byrne NP, Henry JC, Hermann DN, et al. Neuropatholocial findings in an Guillain-Barre patient with strokes after IVIg therapy. Neurology. 2002;59:458-461.
24. Emerson GG, Herndon CN, Sreih AG. Thrombotic complications after intravenous immunoglobulin therapy in two patients. Pharmacotherapy. 2002;22:1638-1641.
25. Caress JB, Cartwright MS, Donofrio PD, Peacock JE Jr. The clinical features of 16 cases of stroke associated with administration of IVIg. Neurology. 2003;60:1822-1824.
26. Dalakas MC, Clark WM. Strokes, thromboembolic events, and IVIg: rare incidents blemish an excellent safety record. Neurology. 2003;60:1736-1737.
27. Hefer D, Jaloudi M. Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: a case report and discussion of the relevant literature. Ann Hematol. 2004;83:661-665.
28. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med. 1994;121:259-262.
29. Scribner CL, Kapit RM, Phillips ET, Rickles NM. Aseptic meningitis and intravenous immunoglobulin therapy. Ann Intern Med. 1994;121:305-306.
30. Boyce TG, Spearman P. Acute aseptic meningitis secondary to intravenous immunoglobulin in a patient with Kawasaki syndrome. Pediatr Infect Dis J. 1998;17:1054-1056.
31. Moris G, Garcia-Monco JC. The challenge of drug-induced aseptic meningitis. Arch Intern Med. 1999;159:1185-1194.
32. Jolles S, Sewell WA, Leighton C. Drug-induced aseptic meningitis: diagnosis and management. Drug Saf. 2000;22:215-226.
33. Obando I, Duran I, Martin-Rosa L, Cano JM, Garcia-Martin FJ. Aseptic meningitis due to administration of intravenous immunoglobulin with an unusually high number of leukocytes in cerebrospinal fluid. Pediatr Emerg Care. 2002;18:429-432.
34. De Vlieghere FC, Peetermans WE, Vermylen J. Aseptic granulocytic meningitis following treatment with intravenous immunoglobulin. Clin Infect Dis. 1994;18:1008-1010.
35. Savige J, Gillis D, Benson E, et al. International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA). Am J Clin Pathol. 1999;111:507-513.
36. Savige J, Dimech W, Fritzler M, et al. Addendum to the international consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies: quality control guidelines, comments, and recommendations for testing in other autoimmune diseases. Am J Clin Pathol. 2003;120:312-318.
37. Savige JA, Paspaliaris B, Silvestrini R, et al. A review of immunofluorescent patterns associated with antineutrophil cytoplasmic antibodies (ANCA) and their differentiation from other antibodies. J Clin Pathol. 1998;51:568-575.
38. Rothe G, Valet G. Flow cytometric assays of oxidative burst activity in phagocytes. Methods Enzymol. 1994;233:539-548.
39. Hofstaetter T, Gronski P, Kanzy EJ, Schorlemmer HU, Seiler FR. S-sulfonation: a reversible chemical modification of human immunoglobulins permitting intravenous application, II: effect on Fcmediated effector functions. Vox Sang. 1983;45:155-165.
40. Jolles S, Deacock S, Turnbull W, et al. Atypical C-ANCA following high dose intravenous immunoglobulin. J Clin Pathol. 1999;52:177-180.
41. Ayliffe W, Haeney M, Roberts SC, Lavin M. Uveitis after antineutrophil cytoplasmic antibody contamination of immunoglobulin replacement therapy. Lancet. 1992;339:558-559.
42. Donatini B, Goetz J, Hauptmann G. Uveitis and antineutrophil cytoplasmic antibody in immunoglobulin batches. Lancet. 1992;339:1175-1176.
43. Borregaard N, Cowland JB. Granules of the human neutrophilic polymorphonuclear leukocyte. Blood. 1997;89:3503-3521.
44. Savige J, Davis D, Falk R, Jennette JC, Wiik A. Antineutrophil cytoplasmic antibodies and associated diseases: a review of the clinical and laboratory features. Kidney Int. 2000;57:846-862.
45. Avrameas S. Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. Immunol Today. 1991;12:154-159.
46. Coutinho A, Kazatchkine MD, Avrameas S. Natural autoantibodies. Curr Opin Immunol. 1995;7:812-818.
47. Lacroix-Desmazes S, Kaveri SV, Mouthon L, et al. Self-reactive antibodies (natural autoantibodies) in healthy individuals. J Immunol Methods. 1998;216:117-137.
48. Lutz HU, Wipf G. Naturally occurring autoantibodies to skeletal proteins from human red blood cells. J Immun. 1982;128:1695-1699.
49. Cui Z, Wang HY, Zhao MH. Natural autoantibodies against glomerular basement membrane exist in normal human sera. Kidney Int. 2006;69:894-899.
50. Lutz HU. Innate immune and non-immune mediators of erythrocyte clearance. Cell Mol Biol. 2004;50:107-116.
51. Arese P, Turrini F, Schwarzer E. Band 3/complement-mediated recognition and removal of normally senescent and pathological human erythrocytes. Cell Physiol Biochem. 2005;16:133-146.
52. Zhang M, Austen WG, Chiu I, et al. Identification of a specific self-reactive IgM antibody that initiates intestinal ischemia/reperfusion injury. Proc Natl Acad Sci U S A. 2004;101:3886-3891.
53. Kra-Oz Z, Lorber M, Shoenfeld Y, Scharff Y. Inhibitor(s) of natural anti-cardiolipin autoantibodies. Clin Exp Immunol. 1993;93:265-268.
54. Al-Ghamdi H, Mustafa M, Al-Fawaz I, Al-Dowaish A. Acute aseptic meningitis associated with administration of immunoglobulin in children: a case report and review of the literature. Ann Saudi Med. 1999;19:362-364.
55. Tam DA, Morton LD, Stroncek DF, Leshner RT. Neutropenia in a patient receiving intravenous immune globulin. J Neuroimmunol. 1996;64:175-178.
56. Berkovitch M, Dolinski G, Tauber T, Aladjem M, Kaplinsky C. Neutropenia as a complication of intravenous immunoglobulin (IVIg) therapy in children with immune thrombocyto-penic purpura: common and non-alarming. Int J Immunopharmacol. 1999;21:411-415.
57. Teeling JL, Bleeker WK, Rigter GM, van Rooijen N, Kuijpers TW, Hack CE. Intravenous immunoglobulin preparations induce mild activation of neutrophils in vivo via triggering of macrophages: studies in a rat model. Br J Haematol. 2001;112:1031-1040.
58. Teeling JL, De Groot ER, Eerenberg AJ, et al. Human intravenous immunoglobulin (IVIg) preparations degranulate human neutrophils in vitro. Clin Exp Immunol. 1998;114:264-270.
59. Minagar A, Alexander JS. Blood-brain barrier disruption in multiple sclerosis. Mult Scler. 2003;9:540-549.
60. Brettschneider J, Claus A, Kassubek J, Tumani H. Isolated blood-cerebrospinal fluid barrier dysfunction: prevalence and associated diseases. J Neurol. 2005;252:1067-1073.
61. Abbott NJ, Mendonca LL, Dolman DE. The bloodbrain barrier in systemic lupus erythematosus. Lupus. 2003;12:908-915.